Single Variable Domain Production With Reduced Carbamylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immunoglobulin single variable domains produced in host cells exhibit a significant fraction of product-related variants containing carbamylated amino acid residues, which affect product homogeneity and stability, posing challenges for therapeutic applications.
Innovation Solution
Adapting culturing and purification conditions, such as pH, temperature, and using specific chromatographic techniques like ion-exchange chromatography, to reduce or eliminate carbamylated variants in immunoglobulin single variable domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If immunoglobulin single variable domains are produced in host cells, then production yield is achieved, but carbamylated variants are formed reducing product homogeneity
Solution Approach 1:
The patent applies parameter changes by adjusting pH conditions during production and purification. Specifically, maintaining pH between 6.0-7.5 during culture and using pH 8.0-9.0 for ion-exchange chromatography binding, then lowering to pH 5.0-7.0 for elution. These pH parameter changes prevent carbamylation reactions and enable separation of carbamylated variants, resolving the contradiction between yield and homogeneity.
Solution Approach 2:
The patent employs ion-exchange chromatography to extract and remove carbamylated variants from the immunoglobulin single variable domain product. The chromatography step separates the desired product from carbamylated impurities based on charge differences, effectively taking out the harmful variants while preserving the homogeneous product.
2Ease of manufacture
If conventional production methods are used, then production process is simple, but carbamylated variants reduce therapeutic quality
Solution Approach 1:
The patent modifies conventional production by implementing specific pH parameter control throughout the process. By maintaining pH 6.0-7.5 during cell culture and adjusting to pH 8.0-9.0 for chromatography binding, then pH 5.0-7.0 for elution, the method prevents carbamylation and ensures therapeutic quality without significantly complicating the manufacturing process.
Solution Approach 2:
The patent introduces ion-exchange chromatography as an intermediary purification step between production and final formulation. This intermediate step acts as a mediator to remove carbamylated variants, ensuring therapeutic quality while maintaining overall process simplicity through the use of standard chromatography technology.
3Manufacturing precision
If product purification is enhanced to remove variants, then product homogeneity is improved, but production complexity and cost increase
Solution Approach 1:
The patent achieves product homogeneity through pH parameter optimization rather than complex multi-step purification. By controlling pH at 6.0-7.5 during production and using pH-dependent ion-exchange chromatography (binding at pH 8.0-9.0, elution at pH 5.0-7.0), the method simplifies purification while effectively removing carbamylated variants.
Solution Approach 2:
The patent applies discarding and recovering by selectively removing carbamylated variants through ion-exchange chromatography while recovering the homogeneous immunoglobulin single variable domain product. This approach achieves high purity by discarding only the problematic carbamylated fractions rather than implementing complex purification schemes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods significantly reduce or eliminate carbamylated variants, enhancing product homogeneity and stability, thereby improving the quality and yield of immunoglobulin single variable domains for therapeutic use.
Implementation Method 1
using specific chromatographic techniques like ion-exchange chromatography
Data Source
AI summary
The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.